Mitsubishi UFJ Trust & Banking Corp Sells 2,762 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mitsubishi UFJ Trust & Banking Corp trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,478 shares of the company's stock after selling 2,762 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned 0.06% of IDEXX Laboratories worth $20,456,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories during the third quarter worth approximately $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $31,000. Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories during the 4th quarter valued at $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories in the fourth quarter worth $41,000. Institutional investors own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IDXX. Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Finally, Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $533.75.

Remove Ads

IDEXX Laboratories Trading Down 0.3 %

Shares of NASDAQ IDXX traded down $1.38 during trading hours on Tuesday, reaching $418.57. The stock had a trading volume of 518,227 shares, compared to its average volume of 584,145. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88. The firm has a market cap of $33.93 billion, a price-to-earnings ratio of 39.23, a P/E/G ratio of 3.41 and a beta of 1.39. The business's fifty day moving average price is $436.90 and its two-hundred day moving average price is $441.45. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.